Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aslera Safety "Still Open," FDA Cmte. Says; Surveillance Study Needed

Executive Summary

Genelabs/Watson Aslera should have a surveillance monitoring requirement to generate additional safety information, FDA Arthritis Advisory Committee Acting Chair Nigel Harris, MD, Morehouse School of Medicine, indicated during review of the drug.

You may also be interested in...



Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted

Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.

Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted

Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.

Genelabs Aslera May Offer Some Efficacy For Treatment Of Lupus - FDA Cmte.

Genelabs Aslera may offer some clinical utility for the treatment of patients with mild to moderate systemic lupus erythematosus, FDA Arthritis Advisory Committee members indicated April 19.

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel